Navigation Links
Sundance Diagnostics Developing Antidepressant Suicide Risk Test
Date:12/12/2013

BOULDER, Colo., Dec. 12, 2013 /PRNewswire/ -- Sundance Diagnostics announces they have entered into an exclusive, worldwide licensing agreement with the Max Planck Institute of Psychiatry, Munich, Germany, to expand the Institute's initial clinical validation of genetic markers and to commercialize a genetic test that predicts risk of suicide emerging from use of antidepressant drugs. 

(Photo: http://photos.prnewswire.com/prnh/20131212/AQ32409)

The test is to enable physicians to decrease the risk of suicide in patients treated with single antidepressant drugs and combinations of psychiatric medications. 

According to IMS Health, there are over 9 million new patient prescriptions written each year in the U.S.  An additional 9 million new patient prescriptions are estimated to be written yearly worldwide. 

The company is preparing for the launch of the test as a laboratory developed test in the United States and Europe and will announce in early 2014 when it will be available.  In addition, clinical studies will be initiated in support of a U.S. Food and Drug Administration submission for market clearance, European CE marking and insurance reimbursement.  The company plans for applications to be submitted to the regulatory agencies within 18 months.

The Max Planck scientific team was led by Andreas Menke, M.D. and Elisabeth Binder, M.D. Ph.D.  The scientists discovered 79 genetic markers that had a 91% probability of correctly classifying patients at risk of antidepressant-induced suicide in an independent replication study. 

Of the 8.1% of patients who developed antidepressant-induced suicidality in the Institute's study, nearly 60% experienced the serious side effect within two weeks of beginning treatment.

Contrary to the current FDA warning that persons under the age of 25 have the greatest risk, study results indicated there was no age difference between those who developed suicidal ideation and those who did not.  Scientists at the National Institute of Mental Health (NIMH), in their 1,900-patient STAR*D study, showed similar data.  

Since 2005 all antidepressant drugs in the U.S., Canada and a number of European countries have carried the highest level warning for risk of suicide, but doctors have not been able to determine which patients may be at risk – sometimes with tragic results. 

Sundance CEO Kim Bechthold stated, "Our hope is that the new test will assist the physician in significantly reducing the risk of these tragic results and will provide patients and families with valuable personal information to use with their doctors in planning treatment."

Eleven percent of Americans age 12 and over are reported to be taking an antidepressant drug in the CDC's National Health and Nutrition Examination Survey (NHANES).  Antidepressant use increased 400% from the period 1988-1994 through 2005-2008, according to the National Center for Health Statistics. 

The original research, "Genome-Wide Association Study of Antidepressant Treatment-Emergent Suicidal Ideation," was published online in Neuropsychopharmacology  October 26, 2011. 

The licensing agreement was concluded with Max Planck Innovation, the Max Planck Institute´s technology transfer organization.

Sundance Diagnostics' Chief Scientific Advisor is Peter Tolias, Ph.D., Professor and Director of the Stevens Institute of Technology, Center for Healthcare Innovation in Hoboken, New Jersey. 

About Sundance Diagnostics

Sundance Diagnostics, based in Boulder, Colorado, is a diagnostic test developer focusing on genetic companion diagnostic tests to reduce the risk of serious side effects from major-market pharmaceutical medications.  The company has assembled a group of leading scientific and medical experts in genetics, molecular diagnostics, psychiatry and neuropsychopharmacology.

About the Max Planck Institute of Psychiatry

The Max Planck Institute of Psychiatry in a unique way combines basic research, clinical research and patient care in the field of psychiatry and neurology. The main focus of research and clinical treatment options lies on depression and anxiety disorders. In the field of psychiatry, the Max Planck Institute of Psychiatry is regarded as one of the world-wide leading research institutes concentrating on the development of personalized medicine.

Press release contact:

Kim Bechthold,
CEO, Sundance Diagnostics
Phone: 303 862-2770 
kbech@sundancedx.com

Max Planck Institute of Psychiatry contacts:

Dr. Dr. Elisabeth Binder
Managing Director, Max Planck Institute of Psychiatry, Department of Translational Research in Psychiatry and Stress-related Disorders  
Phone: 49 89 30622-1
binder@mpipsykl.mpg.de

Dr. Andreas Menke
Scientist and Resident, Max Planck Institute of Psychiatry, Department of Translational Research in Psychiatry and Stress-related Disorders  
Phone: 49 89 30622-1
menke@mpipsykl.mpg.de                                      


'/>"/>
SOURCE Sundance Diagnostics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sundance Channels Push Girls star, Chelsie Hill, Leads Line Up of New Products, Services and Technology at Abilities Expo-The Nations Leading Expo for People with Disabilities on June 28-30
2. QBC Diagnostics Awarded GSA Contract
3. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
4. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
5. Ariosa Diagnostics to Present and Exhibit at the 16th International Conference on Prenatal Diagnosis and Therapy
6. ZINO Society Targets Medical Devices, Healthcare IT and Diagnostics
7. Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
8. Breakthrough Prostate Cancer Diagnostics
9. NicOx Signs Worldwide Licensing Agreement With Rapid Pathogen Screening, Inc. For Ophthalmic Diagnostics
10. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
11. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... Pa. , June 23, 2016 The ... in an outpatient dialysis facility.  Treatments are usually 3 ... 6 hours per visit, including travel time, equipment preparation ... a patient, but especially grueling for patients who are ... of a skilled nursing and rehabilitation centers for some ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
Breaking Medicine News(10 mins):